Covidien
COV, a leading global provider of healthcare products, today
announced that an independent study conducted by the University of
Edinburgh has successfully demonstrated the effectiveness of Covidien's
Kendall SCD™ system with Vascular Refill Detection Technology on
immobile stroke patients.
An independent study conducted by the University of Edinburgh has successfully demonstrated the effectiveness of Covidien's Kendall SCD(TM) system with Vascular Refill Detection Technology on immobile stroke patients. (Photo: Business Wire)
The results of the CLOTS 3 trial were presented at the European
Stroke Conference by Professor Martin S. Dennis of the University of
Edinburgh's Division of Clinical Neurosciences and also published in The
Lancet. The new study showed a 29.9% decrease in the development
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in